

Foresight[®]

Carrier Screen



We help you care for *every* hopeful parent

Guide every parent-to-be in planning for the path ahead with genetic insights



Myriad
genetics

Health. Illuminated.


Every hopeful parent deserves reliable genetic insights

The goal of carrier screening is to detect couples who are at risk of passing down serious inherited conditions.

The clinical utility of carrier screening is to help at risk couples understand their risk(s) and consider their reproductive,¹ diagnostic testing, newborn screening, and treatment options.

ACOG and ACMG recommend carrier screening to **every** patient considering pregnancy or who is already pregnant.^{1,2}

Understanding carrier screening status can help families get to a diagnosis, and possibly treatment, faster.



7.3 – number of physicians visited before getting a rare disease diagnosis⁴



4.8 years – average time it takes to diagnose a rare disease from symptom onset⁴



18% – infant hospitalizations in the US due to recessive genetic conditions⁵

Foresight® Carrier Screen helps you identify couples—of every ancestry—who are at risk to pass down serious, prevalent, clinically-actionable inherited conditions to their children, giving all your patients clear answers to guide their journey.

1 in 22

1 in 22 couples (screened with the Universal panel) identified at-risk for serious inherited conditions - the highest published detection rate⁶

>99%


>99% detection rate for the vast majority of genes on our panels⁷



Simplify screening for every couple with tandem reflex and merged reports

Tandem reflex streamlines partner carrier screening by:

- Reducing follow-up coordination
- Decreasing turnaround time
- Increasing screening compliance
- Managing cost



This is a final report. Partner testing has been completed.

This is an **amended report**, from the 04/01/2019 original. Merged with previously released report.

Foresight® Carrier Screen

POSITIVE: HIGH REPRODUCTIVE RISK

ABOUT THIS TEST
The Myriad Foresight Carrier Screen utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

PANEL NOTE
Please note that you and your partner were tested for different conditions or genomic regions. The panel name and total number of diseases are listed on the front of the report. See page 6 for disease-specific information by patient.

RESULTS SUMMARY

Risk Details	LILY CATHEY	SHARON DURAN
Panel Information	Foresight Carrier Screen Universal Panel ACOGIACMG/DMD Panel Fundamental Panel Fragile X Syndrome (176 conditions tested)	Foresight Carrier Screen Smith-Lemli-Opitz Syndrome Panel (1 condition tested)
POSITIVE: HIGH REPRODUCTIVE RISK Smith-Lemli-Opitz Syndrome Reproductive Risk: 1 in 4 Inheritance: Autosomal Recessive	CARRIER* NM_001360.2(DHCR7):c.964-1G>C (aka IVS8-1G>C) heterozygote	CARRIER* NM_001360.2(DHCR7):c.964-1G>C (aka IVS8-1G>C) heterozygote

*Carriers generally do not experience symptoms.

No disease-causing mutations were detected in any other gene tested. A complete list of all conditions tested can be found on page 6.

CLINICAL NOTES

- None

NEXT STEPS

- Genetic counseling is recommended and patients may wish to discuss any positive results with blood relatives, as there is an increased chance that they are also carriers.

Merged reports offer a clear view of overall reproductive risk

Carrier screening panels designed with every patient in mind

Myriad Genetics pioneered the first expanded carrier screening to maximize detection of at-risk couples. Our goal is to produce not simply more, but meaningful clinical information. We offer three standard panels:

Fundamental

Cystic fibrosis and spinal muscular atrophy

Fundamental Plus

Guidelines-focused set of 14 genes

Universal

176 genes associated with serious and prevalent inherited conditions

Panels may be customized based on clinical needs

Meet the Pantier family

Real-world impact:

Ashley Pantier shares the positive health impact the Foresight® Carrier Screen has had on her family



1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol.* 2020;136(4):e48-e69. doi:10.1097/AOG.0000000000004084 2. Gregg, A.R., Aarabi, M., Klugman, S. et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med* 23, 1793–1806 (2021). <https://doi.org/10.1038/s41436-021-01203-z> 3. Nguengang Wakap, S., Lambert, D.M., Olry, A. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. *Eur J Hum Genet* 28, 165–173 (2020). <https://doi.org/10.1038/s41431-019-0508-0> 4. Global Genes, Accurate Diagnosis of Rare Diseases Remains Difficult Despite Strong Physician Interest, Published March 6, 2013, Accessed March 21, 2022 <https://globalgenes.org/2014/03/06/accurate-diagnosis-of-rare-diseases-remains-difficult-despite-strong-physician-interest/> 5. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. *PLoS Curr.* 2012;4:e4f9877ab8ffa9. Published 2012 May 2. doi:10.1371/4f9877ab8ffa9 6. Hogan GJ, Vysotskaia VS, Beauchamp KA, et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. *Clin Chem.* 2018;64(7):1063-1073. doi:10.1373/clinchem.2018.286823 7. Based on internal data